Congress deregulates medicine—except abortion, gender care, assisted suicide

What it does

This bill strips the FDA, NIH, and CDC of authority to regulate medical practice and prohibits federal law from restricting off-label drug use. However, it explicitly carves out abortion, assisted suicide, euthanasia, and gender-transition medical interventions from this protection—meaning federal restrictions on those practices remain enforceable. The bill's net effect is to deregulate most medical practice while preserving or enabling federal bans on specific categories of care.

Why we flagged it

The bill's operative mechanism is broad deregulation of medical practice and off-label drug use, but the carve-out in subsection (b) reveals the true character: it is not neutral deregulation but a selective framework that removes federal oversight from most medicine while affirmatively preserving federal authority to restrict abortion, gender-transition care, and assisted suicide. This is deregulation-with-exceptions, not pure deregulation.

What the text implies

• The carve-out in subsection (b) does not merely preserve existing law—it affirmatively signals that federal restrictions on abortion, gender-transition care, and assisted suicide are INTENDED to remain enforceable and may be strengthened. This invites future federal bans on those practices.
• Removing FDA authority to regulate medical practice may eliminate safety oversight for experimental treatments, compounded-drug quality, and off-label prescribing protocols, shifting liability and safety burden to individual physicians and patients.
• The bill's silence on state medical boards and state law means state-level regulation of medicine remains intact, but federal deregulation may create a patchwork where some states allow practices the federal government has banned.
• Off-label drug use without federal restriction may increase access to unapproved medications but also removes FDA's ability to track adverse events, drug interactions, or safety signals across the population.
• The carve-out for 'gender transition medical interventions' is undefined—it is unclear whether it applies only to minors, all ages, all procedures, or specific drugs, creating legal ambiguity that may invite litigation and state-level bans.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens gain prescriber autonomy and access to off-label drugs without federal gatekeeping—a real benefit for patients seeking experimental or alternative treatments. However, the carve-out for gender-transition care, abortion, and assisted suicide means federal bans on those specific medical interventions remain enforceable, potentially restricting access to lawful care in those domains and creating a two-tier system where some medical decisions are deregulated and others are federall

Who stands to gain

• pharmaceutical companies (off-label drug sales without FDA gatekeeping)
• compounding pharmacies (reduced federal oversight of compounded drugs)
• physicians and medical practices (reduced regulatory compliance burden)
• medical device manufacturers (reduced FDA premarket review authority)

Named in the bill

Food and Drug Administration (FDA), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Federal Food, Drug, and Cosmetic Act, section 561B (expanded access pathway)

Where it stands

• May 21, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• May 21, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
• Mar 19, 2026 — Hearing held · Congress.gov: “Committee on Health, Education, Labor, and Pensions. Hearings held”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 3 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $640,433 in lobbying spend. A filing names 30 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Ron Johnson, the sponsor, reported $49,500 in PAC receipts in the 2026 cycle.

• College of American Pathologists — $640,433 on 3 filings

Lobbying Disclosure Act filings through Jul 15, 2026. A filing shows who paid to lobby on a bill it names, not what changed.